Brokerages expect Intercept Pharmaceuticals Inc (NASDAQ:ICPT) to report earnings per share (EPS) of ($4.27) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Intercept Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($4.94) and the highest estimate coming in at ($3.29). Intercept Pharmaceuticals reported earnings of ($3.33) per share in the same quarter last year, which would indicate a negative year over year growth rate of 28.2%. The company is expected to issue its next quarterly earnings report before the market opens on Thursday, May 4th.
According to Zacks, analysts expect that Intercept Pharmaceuticals will report full year earnings of ($16.43) per share for the current fiscal year, with EPS estimates ranging from ($19.08) to ($12.55). For the next year, analysts forecast that the business will report earnings of ($12.77) per share, with EPS estimates ranging from ($17.20) to ($7.75). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Intercept Pharmaceuticals.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($4.84) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.74) by $1.10. The business had revenue of $13 million for the quarter, compared to analyst estimates of $8.96 million. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm’s revenue was up 2966.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($3.62) EPS.
Several research analysts have recently weighed in on ICPT shares. Oppenheimer Holdings Inc. set a $200.00 price target on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, January 11th. Wedbush reiterated an “outperform” rating and set a $224.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, March 17th. Needham & Company LLC downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 20th. Vetr upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $169.70 price target for the company in a research note on Monday, January 9th. Finally, Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research note on Tuesday, January 17th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $187.65.
In other news, CMO David Shapiro sold 558 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $108.51, for a total transaction of $60,548.58. Following the completion of the sale, the chief marketing officer now owns 45,465 shares in the company, valued at approximately $4,933,407.15. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Lisa Bright sold 389 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $115.00, for a total value of $44,735.00. Following the sale, the insider now owns 22,925 shares of the company’s stock, valued at approximately $2,636,375. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,682 shares of company stock valued at $190,137. 9.20% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of ICPT. ING Groep NV acquired a new stake in shares of Intercept Pharmaceuticals during the fourth quarter worth about $2,120,000. BlackRock Institutional Trust Company N.A. increased its stake in shares of Intercept Pharmaceuticals by 5.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 437,337 shares of the biopharmaceutical company’s stock worth $71,981,000 after buying an additional 21,523 shares during the period. Emerald Advisers Inc. PA increased its stake in shares of Intercept Pharmaceuticals by 43.7% in the third quarter. Emerald Advisers Inc. PA now owns 76,079 shares of the biopharmaceutical company’s stock worth $12,522,000 after buying an additional 23,129 shares during the period. Opus Point Partners Management LLC increased its stake in shares of Intercept Pharmaceuticals by 63.5% in the fourth quarter. Opus Point Partners Management LLC now owns 2,135 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 829 shares during the period. Finally, State Street Corp increased its stake in shares of Intercept Pharmaceuticals by 20.2% in the fourth quarter. State Street Corp now owns 751,027 shares of the biopharmaceutical company’s stock worth $81,600,000 after buying an additional 126,011 shares during the period. Hedge funds and other institutional investors own 82.28% of the company’s stock.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.78% on Thursday, reaching $112.35. The company’s stock had a trading volume of 214,987 shares. The firm’s 50-day moving average price is $114.23 and its 200-day moving average price is $115.18. Intercept Pharmaceuticals has a 12 month low of $96.63 and a 12 month high of $177.93. The stock’s market cap is $2.79 billion.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.